Immunome Inc
IMNM8.680USD
-0.240-2.69%
Handelsschluss 06/25, 16:00（ET）Kurse um 15 Minuten verzögert
754.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immunome Inc Unternehmen
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Unternehmensinformationen
BörsenkürzelIMNM
Name des UnternehmensImmunome Inc
IPO-datumOct 02, 2020
Gegründet am2015
CEODr. Clay B. Siegall, Ph.D.
Anzahl der mitarbeiter118
WertpapierartOrdinary Share
GeschäftsjahresendeOct 02
Addresse18702 N. Creek Parkway
StadtBOTHELL
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl98011
Telefon16103213700
Websitehttps://immunome.com/
BörsenkürzelIMNM
IPO-datumOct 02, 2020
Gegründet am2015
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Umsatzaufteilung
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
9.04M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
33.48%
Investment Advisor/Hedge Fund
29.43%
Hedge Fund
14.85%
Corporation
8.26%
Research Firm
4.28%
Individual Investor
3.23%
Venture Capital
0.91%
Bank and Trust
0.29%
Pension Fund
0.14%
Other
5.14%
Institutionelle Beteiligung
Aktualisiert: Mon, Mar 3
Aktualisiert: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
295
69.73M
91.15%
+848.96K
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
2022Q4
98
4.36M
36.09%
-940.25K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
5.50M
6.33%
-262.06K
-4.55%
Dec 31, 2024
Redmile Group, LLC
4.83M
5.55%
-61.53K
-1.26%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.74M
4.3%
+134.54K
+3.73%
Dec 31, 2024
Enavate Sciences GP, LLC
3.48M
4%
+3.48M
--
Dec 31, 2024
The Vanguard Group, Inc.
3.00M
3.45%
-128.13K
-4.10%
Dec 31, 2024
EcoR1 Capital, LLC
3.88M
4.46%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
3.92M
4.51%
-305.48K
-7.23%
Dec 31, 2024
Opaleye Management Inc.
2.04M
2.35%
+802.50K
+64.85%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
WisdomTree BioRevolution Fund
0.97%
iShares Genomics Immunology and Healthcare ETF
0.71%
ALPS Medical Breakthroughs ETF
0.63%
Virtus LifeSci Biotech Clinical Trials ETF
0.5%
Main Thematic Innovation ETF
0.5%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Nuveen ESG Small-Cap ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
Mehr Anzeigen
WisdomTree BioRevolution Fund
Anteil0.97%
iShares Genomics Immunology and Healthcare ETF
Anteil0.71%
ALPS Medical Breakthroughs ETF
Anteil0.63%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.5%
Main Thematic Innovation ETF
Anteil0.5%
SPDR S&P Biotech ETF
Anteil0.2%
iShares Micro-Cap ETF
Anteil0.15%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.13%
Nuveen ESG Small-Cap ETF
Anteil0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
Anteil0.05%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
